Beodeul Kang

Prof. Dr. Beodeul Kang

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
IKIn-Ho Kim
In-Ho Kim
SKSeung Joo Kang
Seung Joo Kang
WCWonyoung Choi
Wonyoung Choi
ASAn Na Seo
An Na Seo
BEBang Wool Eom
Bang Wool Eom
OTon behalf of The Development Working Group for the Korean Practice Guideline for Gastric Cancer 2024 Task Force Team
on behalf of The Development Working Group for the Korean Practice Guideline for Gastric Cancer 2024 Task Force Team
Kim IH, et al. J Gastric Cancer. 2025 Jan;25:e11. https://doi.org/10.5230/jgc.2025.25.e11

19 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HKHyung-Don Kim
Hyung-Don Kim
SJSeyoung Jung
Seyoung Jung
HLHo Yeong Lim
Ho Yeong Lim
BRBaek-Yeol Ryoo
Baek-Yeol Ryoo
MRMin-Hee Ryu
Min-Hee Ryu
CYChanghoon Yoo
Changhoon Yoo
Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib–nivolumab as front-line treatment for uHCC. Forty-two patients received nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). ORR per RECIST version 1.1 was 31.0%, meeting the primary endpoint. The most common adverse events were palmar-plantar erythrodysesthesia syndrome (38.1%), alopecia (26.2%) and skin rash (23.8%). Median PFS was 7.38 months. The 1-year OS rate was 80.5%, and the median OS was not reached. Exploratory single-cell RNA sequencing analyses of peripheral blood mononuclear cells showed that long-term responders exhibited T cell receptor repertoire diversification, enrichment of genes representing immunotherapy responsiveness in MKI67+ proliferating CD8+ T cells and a higher probability of M1-directed monocyte polarization. Our data support further clinical development of the regorafenib–nivolumab combination as front-line treatment for uHCC and provide preliminary insights on immune biomarkers of response. ClinicalTrials.gov identifier: NCT04310709.

29 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BKBeom Kyung Kim
Beom Kyung Kim
JCJaekyung Cheon
Jaekyung Cheon
HKHyeyeong Kim
Hyeyeong Kim
BKBeodeul Kang
Beodeul Kang
YHYeonjung Ha
Yeonjung Ha
HCHong Jae Chon
Hong Jae Chon
Lenvatinib (LENV) and atezolizumab/bevacizumab (ATE/BEV) have been approved as first-line regimens for the treatment of unresectable hepatocellular carcinoma (HCC). We aimed to compare their clinical efficacy and safety. Patients receiving ATE/BEV (n = 86) or LENV (n = 146) as first-line treatment were recruited from three academic hospitals in Korea. Overall survival (OS), progression-free survival (PFS), and radiological response were assessed according to the Response Evaluation Criteria in Solid Tumors. Clinical features of the two groups were balanced through propensity score (PS) matching with a 1:1 ratio and inverse probability of treatment weighting (IPTW) analyses. The median age was 62 years, with male predominance (83.6%). There was no significant difference in the objective response rate between the ATE/BEV and LENV groups (32.6% vs. 31.5%; p = 0.868). Neither median OS (not reached vs. 12.8 months; p = 0.357) nor PFS (5.7 vs. 6.0 months; p = 0.738) was different between ATE/BEV and LENV groups. PS-matched and IPTW analyses yielded comparable results in terms of OS and PFS (all p > 0.05). Grade ≥ 3 adverse events occurred in 42.8% and 21.9% of patients in the ATE/BEV and LENV groups, respectively (p = 0.141). The two first-line therapy regimens for unresectable HCC had comparable clinical efficacy and safety in real-world practice settings. Further studies with a larger sample size and longer follow-up are needed to validate these results.

4 July 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SLSun Min Lim
Sun Min Lim
YKYoun Nam Kim
Youn Nam Kim
KPKi Hyun Park
Ki Hyun Park
BKBeodeul Kang
Beodeul Kang
HCHong Jae Chon
Hong Jae Chon
SRSun Young Rha
Sun Young Rha
Bone metastasis is relatively uncommon in gastric cancer patients, but its incidence has been rising. Early detection of bone metastasis is important in preventing complications related to bone metastasis such as pain, fracture and the compromise of chemotherapy. In this pilot study, we investigated the feasibility of bone turnover markers as surrogate markers of bone metastasis in gastric cancer patients. Fifty-eight patients with gastric cancer were included in this study. Serum levels of bone alkaline phosphatase (ALP), parathyroid hormone (PTH), 25(OH) D, osteocalcin (OC) and C terminal telopeptide were measured and compared between patients with bone metastasis and those without. Student’s t-test and Mann-Whitney U test were used in comparing two groups, and Spearman’s rank order correlation coefficient was calculated to quantify the strength of the associations. Fifty eight age- and sex-matched patients were evaluated for bone turnover markers, among whom 29 patients had bone metastasis and 29 patients with no bone metastasis. The median age was 62 and there were 20 (68.9 %) males and 9 (31.1 %) females in each group. Bone ALP was significantly higher in the patient group (57.32 ± 46.83 vs. 34.57 ± 21.57, P = 0.037) than control group. Bone ALP was positively associated with ALP, osteocalcin, CA19-9, CA 72–4 and negatively associated with 25(OH) D. According to ROC-curve analysis, at the threshold value of 29.60 μg/L, the sensitivity of bone ALP was 76.7 % and the specificity was 59.4 %. Bone ALP may be a surrogate marker of bone metastasis in gastric cancer patients. More prospective studies are warranted to determine the optimal bone turnover markers in the evaluation of bone metastasis.

23 August 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CKChan Kim
Chan Kim
HCHong Jae Chon
Hong Jae Chon
BKBeodeul Kang
Beodeul Kang
KKKiyeol Kim
Kiyeol Kim
HJHei-Cheul Jeung
Hei-Cheul Jeung
SRSun Young Rha
Sun Young Rha
Background: Due to improved survival rate, gastric cancer (GC) patients have an increased risk of developing multiple primary cancer (MPC). The purpose of this study is to evaluate the clinicopathological features of MPC and to generate useful tools for the prediction of metachronous MPC following gastrectomy. Methods: 3066 patients who underwent curative resection of GC were reviewed retrospectively, based on the clinical information and the medical record. Results: The 5-year incidence of MPC was 2.5%. Of these, 54.3% had a metachronous MPC, while 45.7% had a synchronous MPC. The most prevalent site of metachronous MPC was the colorectum (26.3%), followed by lung (23.7%) and liver (18.4%). Multivariate logistic regression analysis revealed that old age at the time of GC diagnosis (≥60 years), early stage of GC (stage I and II), and multiplicity of GC at the time of gastrectomy were independent predictive factors for metachronous MPC. GC patients with either metachronous or synchronous MPC showed poorer survival than patients without MPC. In addition, patients with a metachronous MPC showed late survival disadvantage, while patients with a synchronous MPC showed early survival disadvantage. Furthermore, we were able to develop and internally validate a nomogram to predict the metachronous MPC after curative gastrectomy (C-index = 0.72). Conclusion: Patients at high risk of developing metachronous MPC after curative resection of GC were identified. Individual risk of developing metachronous MPC could be predicted by a novel nomogram. Further external validation with independent patient cohorts is required to improve the accuracy of prediction.

1 January 2014 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
HCHye Jin Choi
Hye Jin Choi
JLJeong Won Lee
Jeong Won Lee
BKBeodeul Kang
Beodeul Kang
SSSong si young Song
Song si young Song
JLJong Doo Lee
Jong Doo Lee
JLJae-Hoon Lee
Jae-Hoon Lee
Choi HJ, et al. Yonsei Med J. 2014 Nov;55(6):1498-1506. https://doi.org/10.3349/ymj.2014.55.6.1498